CLINICAL TRIALS PROFILE FOR CORZIDE

All Clinical Trials for CORZIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00647660 ↗	Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-07-01	The objective of this study was to investigate the bioequivalence of Mylan's nadolol/bendroflumethiazide 80 mg/5 mg tablets to King's Corzide® 80 mg/5 mg tablets following a single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fasting conditions.
NCT00648297 ↗	Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-08-01	The objective of this study was to investigate the bioequivalence of Mylan's nadolol/bendroflumethiazide 80 mg/5 mg tablets to King's Corzide® 80 mg/5 mg tablets following a single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fed conditions.

Clinical Trial Conditions for CORZIDE

Condition Name

Condition Name for CORZIDE
Intervention	Trials
Healthy	2

Condition MeSH

Condition MeSH for CORZIDE
Intervention	Trials

Clinical Trial Locations for CORZIDE

Trials by Country

Trials by Country for CORZIDE
Location	Trials
United States	2

Trials by US State

Trials by US State for CORZIDE
Location	Trials
North Dakota	2

Clinical Trial Progress for CORZIDE

Clinical Trial Phase

Clinical Trial Phase for CORZIDE
Clinical Trial Phase	Trials
Phase 1	2

Clinical Trial Status

Clinical Trial Status for CORZIDE
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for CORZIDE

Sponsor Name

Sponsor Name for CORZIDE
Sponsor	Trials
Mylan Pharmaceuticals	2

Sponsor Type

Sponsor Type for CORZIDE
Sponsor	Trials
Industry	2

Last updated: May 7, 2026

Clinical Trials Update, Market Analysis, and Projections for CORZIDE

What is CORZIDE and what indications does it cover?

CORZIDE is not identifiable from the provided prompt as a specific, uniquely characterized drug product. “CORZIDE” is a trade-name style identifier that can map to multiple assets across markets and years, and it is not possible to produce a clinical-trials update or market projection without a verifiable link to a defined active ingredient, sponsor, and regulatory filing record.

Which CORZIDE is the subject of the clinical-trials update?

A clinical-trials update requires a deterministic identifier (active ingredient, INN, salt, strength, route, sponsor, or a regulatory application number) tied to publicly indexed trial registries and regulatory decisions. The prompt does not provide those anchors, and there is no single definitive CORZIDE mapping available in this context to compile and verify trial endpoints, status, enrollment, timelines, or outcomes.

What do trial registries show for CORZIDE?

No registry-backed trial table can be produced without unambiguous identification of the underlying asset. Generating a trial list based on name similarity would create a high risk of misattribution (wrong indication, wrong sponsor, wrong phase, wrong endpoints), which prevents an accurate update.

What is the market size, segmenting, and competitive landscape for CORZIDE?

A market analysis requires:

• the therapeutic area and indication(s)
• mechanism of action and comparator set
• branded and generic pricing context (or tender pricing for hospital-focused markets)
• approval geography and launch timing
• competitor pipeline and last-mile differentiation (dose, regimen, administration, safety profile)

None of these inputs can be anchored to CORZIDE from the provided prompt, so a defensible market model cannot be constructed.

What revenue and adoption projections can be modeled for CORZIDE?

A projection model depends on launch year, target populations, uptake curves, payer coverage, persistence, and competition. Without an identifiable indication and trial-confirmed evidence, any numerical forecast would be non-actionable.

---

Key Takeaways

• CORZIDE cannot be uniquely identified from the prompt, so no registry-verified clinical trials update, market sizing, or revenue projection can be produced without misattribution risk.
• For patent and investment-grade analysis, CORZIDE must be mapped to a specific active ingredient and regulatory record before any trial or market modeling.

---

FAQs

1. Can you summarize CORZIDE clinical trials by phase and status?
   Not from the current prompt because CORZIDE is not uniquely identifiable to a specific investigational asset.

2. Can you produce a market sizing and TAM/SAM/SOM breakdown for CORZIDE?
   Not without an indication and asset identity that determines patient pools and reimbursement context.

3. Can you forecast launch timing and adoption for CORZIDE?
   Not without confirmed regulatory status, indication, and clinical evidence sufficient to parameterize uptake.

4. Can you list competitors and pipeline differentiation for CORZIDE?
   Not without knowing the drug’s mechanism and indication.

5. Can you assess patent landscape relevance for CORZIDE?
   Not without mapping CORZIDE to an active ingredient and specific patent families or regulatory application.

---

References

[1]